4.7(top 5%)
impact factor
732(top 20%)
papers
20.0K(top 10%)
citations
70(top 10%)
h-index
4.9(top 5%)
impact factor
853
all documents
21.9K
doc citations
102(top 10%)
g-index

Top Articles

#TitleJournalYearCitations
1Current and future treatments for Alzheimer’s diseaseTherapeutic Advances in Neurological Disorders2013478
2Sex and gender issues in multiple sclerosisTherapeutic Advances in Neurological Disorders2013368
3The cognitive impact of antiepileptic drugsTherapeutic Advances in Neurological Disorders2011289
4Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapiesTherapeutic Advances in Neurological Disorders2021259
5Assessment scales in dementiaTherapeutic Advances in Neurological Disorders2012244
6Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overviewTherapeutic Advances in Neurological Disorders2015240
7Best practice in the management of behavioural and psychological symptoms of dementiaTherapeutic Advances in Neurological Disorders2017195
8Review: Deep brain stimulation in Parkinson’s diseaseTherapeutic Advances in Neurological Disorders2009176
9Progressive multifocal leukoencephalopathy: current treatment options and future perspectivesTherapeutic Advances in Neurological Disorders2015175
10Danger signals in stroke and their role on microglia activation after ischemiaTherapeutic Advances in Neurological Disorders2018165
11Myoclonic disorders: a practical approach for diagnosis and treatmentTherapeutic Advances in Neurological Disorders2011159
12Potential neurological symptoms of COVID-19Therapeutic Advances in Neurological Disorders2020158
13Treatment strategies for autoimmune encephalitisTherapeutic Advances in Neurological Disorders2018156
14Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis?Therapeutic Advances in Neurological Disorders2012152
15Treatment options in trigeminal neuralgiaTherapeutic Advances in Neurological Disorders2010150
16Review: Diagnosis and treatment of cerebral vasculitisTherapeutic Advances in Neurological Disorders2010147
17Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision modelTherapeutic Advances in Neurological Disorders2015145
18Defining distinct features of anti-MOG antibody associated central nervous system demyelinationTherapeutic Advances in Neurological Disorders2018137
19Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune systemTherapeutic Advances in Neurological Disorders2018136
20Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for useTherapeutic Advances in Neurological Disorders2015134
21Review: Blood pressure and dementia — a comprehensive reviewTherapeutic Advances in Neurological Disorders2009133
22Multiple sclerosis and pregnancy: experience from a nationwide database in GermanyTherapeutic Advances in Neurological Disorders2012132
23Response of patients with refractory myasthenia gravis to rituximab: a retrospective studyTherapeutic Advances in Neurological Disorders2011131
24Treatment strategies for tics in Tourette syndromeTherapeutic Advances in Neurological Disorders2011130
25When myasthenia gravis is deemed refractory: clinical signposts and treatment strategiesTherapeutic Advances in Neurological Disorders2018129
26Review: Pathophysiology and treatment of bacterial meningitisTherapeutic Advances in Neurological Disorders2009128
27Smoking: effects on multiple sclerosis susceptibility and disease progressionTherapeutic Advances in Neurological Disorders2012126
28Possible clinical outcome measures for clinical trials in patients with multiple sclerosisTherapeutic Advances in Neurological Disorders2010125
29Treatment of glioblastoma in adultsTherapeutic Advances in Neurological Disorders2018117
30Neurological manifestations and implications of COVID-19 pandemicTherapeutic Advances in Neurological Disorders2020114
31Current and emerging therapies in multiple sclerosis: a systematic reviewTherapeutic Advances in Neurological Disorders2012112
32Atacicept: targeting B cells in multiple sclerosisTherapeutic Advances in Neurological Disorders2010111
33A review of the use of magnetic resonance imaging in Parkinson’s diseaseTherapeutic Advances in Neurological Disorders2014111
34Disease-modifying treatments for Alzheimer’s diseaseTherapeutic Advances in Neurological Disorders2011110
35Repetitive transcranial magnetic stimulation in stroke rehabilitation: review of the current evidence and pitfallsTherapeutic Advances in Neurological Disorders2019109
36Review: Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisitedTherapeutic Advances in Neurological Disorders2008107
37Reversible cerebral vasoconstriction syndrome: an under-recognized clinical emergencyTherapeutic Advances in Neurological Disorders2010106
38Anxiety in Parkinson’s disease: identification and managementTherapeutic Advances in Neurological Disorders2014106
39Current approaches to the treatment of paraneoplastic encephalitisTherapeutic Advances in Neurological Disorders2011105
40Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challengesTherapeutic Advances in Neurological Disorders2013103
41The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospectsTherapeutic Advances in Neurological Disorders2016103
42Antisense oligonucleotides in neurological disordersTherapeutic Advances in Neurological Disorders2018100
43MRI in the assessment and monitoring of multiple sclerosis: an update on best practiceTherapeutic Advances in Neurological Disorders201799
44Magnetic resonance monitoring of lesion evolution in multiple sclerosisTherapeutic Advances in Neurological Disorders201398
45Review: Therapy for Alzheimer's disease: how effective are current treatments?Therapeutic Advances in Neurological Disorders200995
46Management of women with multiple sclerosis through pregnancy and after childbirthTherapeutic Advances in Neurological Disorders201692
47Management of sexual dysfunction in Parkinson’s diseaseTherapeutic Advances in Neurological Disorders201191
48An update on best practice of deep brain stimulation in Parkinson’s diseaseTherapeutic Advances in Neurological Disorders201991
49Management of vestibular migraineTherapeutic Advances in Neurological Disorders201190
50Ocrelizumab: a new milestone in multiple sclerosis therapyTherapeutic Advances in Neurological Disorders201890